ES2401269B1 - Composiciones para su uso en el tratamiento y/o prevención del cáncer colorrectal - Google Patents
Composiciones para su uso en el tratamiento y/o prevención del cáncer colorrectal Download PDFInfo
- Publication number
- ES2401269B1 ES2401269B1 ES201131772A ES201131772A ES2401269B1 ES 2401269 B1 ES2401269 B1 ES 2401269B1 ES 201131772 A ES201131772 A ES 201131772A ES 201131772 A ES201131772 A ES 201131772A ES 2401269 B1 ES2401269 B1 ES 2401269B1
- Authority
- ES
- Spain
- Prior art keywords
- peg
- grams
- composition according
- block copolymer
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 140
- 206010009944 Colon cancer Diseases 0.000 title claims abstract description 76
- 208000001333 Colorectal Neoplasms Diseases 0.000 title claims abstract description 70
- 230000002265 prevention Effects 0.000 title claims abstract description 16
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 251
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 250
- 238000000034 method Methods 0.000 claims abstract description 63
- 229920001577 copolymer Polymers 0.000 claims abstract description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 83
- 229930195725 Mannitol Natural products 0.000 claims description 83
- 239000000594 mannitol Substances 0.000 claims description 83
- 235000010355 mannitol Nutrition 0.000 claims description 83
- 239000008141 laxative Substances 0.000 claims description 82
- 239000008247 solid mixture Substances 0.000 claims description 69
- 239000007787 solid Substances 0.000 claims description 68
- 229920001400 block copolymer Polymers 0.000 claims description 60
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 46
- 229960003511 macrogol Drugs 0.000 claims description 46
- 241000282414 Homo sapiens Species 0.000 claims description 40
- 239000000796 flavoring agent Substances 0.000 claims description 39
- 235000019634 flavors Nutrition 0.000 claims description 39
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 38
- 230000002475 laxative effect Effects 0.000 claims description 37
- 239000000314 lubricant Substances 0.000 claims description 34
- 229940125722 laxative agent Drugs 0.000 claims description 25
- 235000019359 magnesium stearate Nutrition 0.000 claims description 19
- 241000282412 Homo Species 0.000 claims description 18
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 15
- 229960001375 lactose Drugs 0.000 claims description 15
- 239000008101 lactose Substances 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 13
- -1 flavorings Substances 0.000 claims description 12
- 235000003599 food sweetener Nutrition 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 12
- 239000003765 sweetening agent Substances 0.000 claims description 12
- 206010010774 Constipation Diseases 0.000 claims description 10
- 229920002472 Starch Polymers 0.000 claims description 8
- 235000006679 Mentha X verticillata Nutrition 0.000 claims description 7
- 235000002899 Mentha suaveolens Nutrition 0.000 claims description 7
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims description 7
- 238000011161 development Methods 0.000 claims description 7
- 239000008107 starch Substances 0.000 claims description 7
- 235000019698 starch Nutrition 0.000 claims description 7
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 5
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 5
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 235000005911 diet Nutrition 0.000 claims description 5
- 239000003792 electrolyte Substances 0.000 claims description 5
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 5
- 239000000600 sorbitol Substances 0.000 claims description 5
- 239000000811 xylitol Substances 0.000 claims description 5
- 235000010447 xylitol Nutrition 0.000 claims description 5
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 5
- 229960002675 xylitol Drugs 0.000 claims description 5
- 208000035984 Colonic Polyps Diseases 0.000 claims description 4
- 229920002261 Corn starch Polymers 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 201000002758 colorectal adenoma Diseases 0.000 claims description 4
- 239000008120 corn starch Substances 0.000 claims description 4
- 238000013461 design Methods 0.000 claims description 4
- 229940096516 dextrates Drugs 0.000 claims description 4
- 230000037213 diet Effects 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000000845 maltitol Substances 0.000 claims description 4
- 235000010449 maltitol Nutrition 0.000 claims description 4
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 4
- 229940035436 maltitol Drugs 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims description 3
- 241000700159 Rattus Species 0.000 claims description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 3
- 238000002052 colonoscopy Methods 0.000 claims description 3
- QPADNTZLUBYNEN-UHFFFAOYSA-N etallobarbital Chemical compound C=CCC1(CC)C(=O)NC(=O)NC1=O QPADNTZLUBYNEN-UHFFFAOYSA-N 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 230000003204 osmotic effect Effects 0.000 claims description 3
- 229920001993 poloxamer 188 Polymers 0.000 claims description 3
- 229920001451 polypropylene glycol Polymers 0.000 claims description 3
- 239000001103 potassium chloride Substances 0.000 claims description 3
- 235000011164 potassium chloride Nutrition 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 3
- 235000011152 sodium sulphate Nutrition 0.000 claims description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 2
- 208000008051 Hereditary Nonpolyposis Colorectal Neoplasms Diseases 0.000 claims description 2
- 206010051922 Hereditary non-polyposis colorectal cancer syndrome Diseases 0.000 claims description 2
- 201000005027 Lynch syndrome Diseases 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 239000004698 Polyethylene Substances 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 230000001594 aberrant effect Effects 0.000 claims description 2
- 230000033228 biological regulation Effects 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 229960001021 lactose monohydrate Drugs 0.000 claims description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims description 2
- 229920000573 polyethylene Polymers 0.000 claims description 2
- 229920005862 polyol Polymers 0.000 claims description 2
- 150000003077 polyols Chemical class 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 102220240796 rs553605556 Human genes 0.000 claims 1
- 235000011008 sodium phosphates Nutrition 0.000 claims 1
- 229920001983 poloxamer Polymers 0.000 abstract 1
- 229960001855 mannitol Drugs 0.000 description 76
- 208000006265 Renal cell carcinoma Diseases 0.000 description 33
- 208000019465 refractory cytopenia of childhood Diseases 0.000 description 33
- 238000005554 pickling Methods 0.000 description 18
- 238000009472 formulation Methods 0.000 description 14
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 13
- 238000012545 processing Methods 0.000 description 12
- 238000003745 diagnosis Methods 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000009967 tasteless effect Effects 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 5
- 235000002639 sodium chloride Nutrition 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000004810 polytetrafluoroethylene Substances 0.000 description 4
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 4
- 229960002920 sorbitol Drugs 0.000 description 4
- 229910001220 stainless steel Inorganic materials 0.000 description 4
- 239000010935 stainless steel Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 235000011888 snacks Nutrition 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 2
- 206010061424 Anal cancer Diseases 0.000 description 2
- 208000007860 Anus Neoplasms Diseases 0.000 description 2
- DGAKHGXRMXWHBX-ONEGZZNKSA-N Azoxymethane Chemical compound C\N=[N+](/C)[O-] DGAKHGXRMXWHBX-ONEGZZNKSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 244000024675 Eruca sativa Species 0.000 description 2
- 235000014755 Eruca sativa Nutrition 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 239000000619 acesulfame-K Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 201000011165 anus cancer Diseases 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001055 chewing effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000010030 laminating Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 244000144927 Aloe barbadensis Species 0.000 description 1
- 235000002961 Aloe barbadensis Nutrition 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 206010048832 Colon adenoma Diseases 0.000 description 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 150000000994 L-ascorbates Chemical class 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 240000001890 Ribes hudsonianum Species 0.000 description 1
- 235000016954 Ribes hudsonianum Nutrition 0.000 description 1
- 235000001466 Ribes nigrum Nutrition 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 244000290333 Vanilla fragrans Species 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910001508 alkali metal halide Inorganic materials 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 229940069978 calcium supplement Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 235000015111 chews Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000002192 cholecystectomy Methods 0.000 description 1
- QBPFLULOKWLNNW-UHFFFAOYSA-N chrysazin Chemical compound O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O QBPFLULOKWLNNW-UHFFFAOYSA-N 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 229960001577 dantron Drugs 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000008368 mint flavor Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 229940030786 moviprep Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 239000002357 osmotic agent Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229940114930 potassium stearate Drugs 0.000 description 1
- ANBFRLKBEIFNQU-UHFFFAOYSA-M potassium;octadecanoate Chemical compound [K+].CCCCCCCCCCCCCCCCCC([O-])=O ANBFRLKBEIFNQU-UHFFFAOYSA-M 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000012954 risk control Methods 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000007473 univariate analysis Methods 0.000 description 1
- 235000019195 vitamin supplement Nutrition 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/77—Polymers containing oxygen of oxiranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1018650 | 2010-11-04 | ||
| GBGB1018650.0A GB201018650D0 (en) | 2010-11-04 | 2010-11-04 | Methods and compositions |
| US41212810P | 2010-11-10 | 2010-11-10 | |
| US61/412128 | 2010-11-10 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2401269A1 ES2401269A1 (es) | 2013-04-18 |
| ES2401269B1 true ES2401269B1 (es) | 2014-02-19 |
Family
ID=43414365
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES201131772A Expired - Fee Related ES2401269B1 (es) | 2010-11-04 | 2011-11-04 | Composiciones para su uso en el tratamiento y/o prevención del cáncer colorrectal |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US20130216493A1 (enExample) |
| EP (1) | EP2635289B1 (enExample) |
| JP (1) | JP5917537B2 (enExample) |
| KR (1) | KR20130109171A (enExample) |
| CN (1) | CN103313719A (enExample) |
| AR (1) | AR083770A1 (enExample) |
| AU (1) | AU2011324996B2 (enExample) |
| BE (1) | BE1019494A3 (enExample) |
| BR (1) | BR112013011012A2 (enExample) |
| CA (1) | CA2816839A1 (enExample) |
| EA (1) | EA201300540A1 (enExample) |
| ES (1) | ES2401269B1 (enExample) |
| GB (1) | GB201018650D0 (enExample) |
| MX (1) | MX349690B (enExample) |
| MY (1) | MY163067A (enExample) |
| NL (1) | NL2007715C2 (enExample) |
| NZ (1) | NZ611145A (enExample) |
| SG (1) | SG189533A1 (enExample) |
| TW (1) | TWI606832B (enExample) |
| UA (1) | UA107998C2 (enExample) |
| WO (1) | WO2012059725A1 (enExample) |
| ZA (1) | ZA201304052B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI535461B (zh) | 2011-03-11 | 2016-06-01 | 諾金私人有限公司 | 結腸清潔溶液、用於製備該溶液之組成物、包含該組成物或溶液之套組、與製備該溶液之方法 |
| BR112015005270B1 (pt) | 2012-09-11 | 2022-11-01 | Norgine Bv | Composição para mistura com água, solução de limpeza de cólon, seus usos e seu kit |
| AR093153A1 (es) * | 2012-10-26 | 2015-05-20 | Northshore Univ Healthsystem | Composiciones que comprenden polietilenglicol para la terapia del carcinoma de celulas escamosas de cabeza y cuello |
| CN103083733A (zh) * | 2013-02-19 | 2013-05-08 | 华熙福瑞达生物医药有限公司 | 一种医用体腔器械导入水性润滑剂 |
| WO2020180581A1 (en) | 2019-03-05 | 2020-09-10 | Dow Global Technologies Llc | Inducing caspase activity |
| US12350288B2 (en) | 2019-03-05 | 2025-07-08 | Dow Global Technologies Llc | Inducing caspase activity |
| EP3934661B1 (en) * | 2019-03-05 | 2025-04-02 | Dow Global Technologies LLC | Inducing caspase activity for treating colorectal cancer with polymers |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2784897B1 (fr) * | 1998-10-27 | 2002-11-29 | Agronomique Inst Nat Rech | Utilisation d'un laxatif osmotique non fermente dans le traitement et la prevention des cancers colorectaux |
| AU2006244112B2 (en) * | 2005-05-06 | 2011-02-17 | Salix Pharmaceuticals, Inc. | Polyethylene glycol colonic purgative composition |
| US8457025B2 (en) * | 2009-08-28 | 2013-06-04 | Telefonaktiebolaget L M Ericsson (Publ) | Method and network node for selecting a network prefix to be advertised in a communication network |
-
2010
- 2010-11-04 GB GBGB1018650.0A patent/GB201018650D0/en not_active Ceased
-
2011
- 2011-04-11 UA UAA201307040A patent/UA107998C2/uk unknown
- 2011-11-04 US US13/883,262 patent/US20130216493A1/en not_active Abandoned
- 2011-11-04 EA EA201300540A patent/EA201300540A1/ru unknown
- 2011-11-04 KR KR1020137013977A patent/KR20130109171A/ko not_active Ceased
- 2011-11-04 CN CN201180064013XA patent/CN103313719A/zh active Pending
- 2011-11-04 MY MYPI2013001602A patent/MY163067A/en unknown
- 2011-11-04 EP EP11785050.3A patent/EP2635289B1/en active Active
- 2011-11-04 AR ARP110104129A patent/AR083770A1/es unknown
- 2011-11-04 JP JP2013537197A patent/JP5917537B2/ja not_active Expired - Fee Related
- 2011-11-04 BE BE2011/0645A patent/BE1019494A3/fr not_active IP Right Cessation
- 2011-11-04 MX MX2013004963A patent/MX349690B/es active IP Right Grant
- 2011-11-04 BR BR112013011012A patent/BR112013011012A2/pt not_active IP Right Cessation
- 2011-11-04 AU AU2011324996A patent/AU2011324996B2/en not_active Ceased
- 2011-11-04 WO PCT/GB2011/001561 patent/WO2012059725A1/en not_active Ceased
- 2011-11-04 TW TW100140231A patent/TWI606832B/zh not_active IP Right Cessation
- 2011-11-04 NZ NZ611145A patent/NZ611145A/en not_active IP Right Cessation
- 2011-11-04 CA CA2816839A patent/CA2816839A1/en not_active Abandoned
- 2011-11-04 SG SG2013032008A patent/SG189533A1/en unknown
- 2011-11-04 ES ES201131772A patent/ES2401269B1/es not_active Expired - Fee Related
- 2011-11-04 NL NL2007715A patent/NL2007715C2/en not_active IP Right Cessation
-
2013
- 2013-06-03 ZA ZA2013/04052A patent/ZA201304052B/en unknown
-
2016
- 2016-04-21 US US15/134,410 patent/US20160228467A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012059725A8 (en) | 2013-05-30 |
| WO2012059725A1 (en) | 2012-05-10 |
| CN103313719A (zh) | 2013-09-18 |
| MY163067A (en) | 2017-08-15 |
| TWI606832B (zh) | 2017-12-01 |
| MX2013004963A (es) | 2013-08-27 |
| EA201300540A1 (ru) | 2013-09-30 |
| BE1019494A3 (fr) | 2012-07-03 |
| AU2011324996A1 (en) | 2013-05-02 |
| KR20130109171A (ko) | 2013-10-07 |
| AU2011324996B2 (en) | 2015-10-08 |
| ZA201304052B (en) | 2014-02-26 |
| JP5917537B2 (ja) | 2016-05-18 |
| UA107998C2 (uk) | 2015-03-10 |
| NZ611145A (en) | 2015-07-31 |
| NL2007715A (en) | 2012-05-07 |
| US20160228467A1 (en) | 2016-08-11 |
| CA2816839A1 (en) | 2012-05-10 |
| EP2635289A1 (en) | 2013-09-11 |
| SG189533A1 (en) | 2013-05-31 |
| NL2007715C2 (en) | 2012-10-16 |
| MX349690B (es) | 2017-08-09 |
| GB201018650D0 (en) | 2010-12-22 |
| AR083770A1 (es) | 2013-03-20 |
| BR112013011012A2 (pt) | 2016-08-23 |
| EP2635289B1 (en) | 2020-03-11 |
| US20130216493A1 (en) | 2013-08-22 |
| JP2013544809A (ja) | 2013-12-19 |
| TW201304785A (zh) | 2013-02-01 |
| ES2401269A1 (es) | 2013-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2405531B1 (es) | Formulaciones sólidas y su uso en el mantenimiento de la salud gastrointestinal | |
| US9089528B2 (en) | Liquid compositions of calcium acetate | |
| ES2401269A1 (es) | Composiciones para su uso en el tratamiento y/o prevención del cáncer colorrectal | |
| ES2319655T3 (es) | Uso de laxantes para tratar el sindrome del intestino irritable. | |
| MX2011009629A (es) | Coposiciones farmaceuticas de liberacion inmediata que comprende oxicodona y naloxona. | |
| BR112020001071A2 (pt) | métodos para reduzir um ou mais sintomas de doença do refluxo gastroesofágico, para tratar uma doença e para tratar/prevenir sinais e/ou sintomas associados com refluxo de ácido biliar, forma de dosagem oral gastrorretentiva, e, composição farmacêutica. | |
| RU2616520C2 (ru) | Лечение симптомов, связанных с гастропарезом у женщин | |
| JP2018035181A (ja) | 組成物の改良及び組成物関連 | |
| JP2013540726A (ja) | 便秘薬 | |
| Patel | Development of Novel Sustained Release Formulations for Older Adults With Swallowing Difficulties | |
| IL225891A (en) | Peg or block peg copolymers for the treatment of colorectal cancer | |
| Van Schoor | Therapeutic use of alkalinising agents: clinical | |
| Van Schoor | Therapeutic use of alkalinising agents in the pharmacy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 2401269 Country of ref document: ES Kind code of ref document: B1 Effective date: 20140219 |
|
| FD2A | Announcement of lapse in spain |
Effective date: 20241230 |